Cite
HARVARD Citation
Wang, Y. et al. (2022). Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence. Cancer medicine. pp. 4491-4500. [Online].